SCI Abstract

search
+
Efficacy of ramucirumab combined with erlotinib or osimertinib in untreated EGFR-mutated NSCLC patients with asymptomatic brain metastases: insights from molecular biomarkers in the RELAY-brain trial
Efficacy of ramucirumab combined with erlotinib or osimertinib in untreated EGFR-mutated NSCLC patients with asymptomatic brain metastases: insights from molecular biomarkers in the RELAY-brain trial
The RELAY-Brain trial examined the clinical utility and survival impacts of ramucirumab (RAM) combined with epidermal grow...
Synergistic antitumor effect of MK-1775 and CUDC-907 against prostate cancer
Synergistic antitumor effect of MK-1775 and CUDC-907 against prostate cancer
Due to the emergence of drug resistance, androgen receptor (AR)-targeted drugs still pose great challenges in the treatmen...
Lenvatinib plus immunotherapy versus lenvatinib monotherapy in lenvatinib-insensitive patients with unresectable hepatocellular carcinoma: a retrospective study
Lenvatinib plus immunotherapy versus lenvatinib monotherapy in lenvatinib-insensitive patients with unresectable hepatocellular carcinoma: a retrospective study
The combination therapy of lenvatinib and immunotherapy as first-line treatment remains controversial in unresectable hepa...
Comprehensive study of gene fusions in sarcomas
Comprehensive study of gene fusions in sarcomas
Sarcomas, including bone sarcomas and soft tissue sarcomas (STSs), are a heterogeneous group of mesenchymal malignancies. ...
A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancer
A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancer
Antiangiogenic drugs may cause vascular normalization and correct hypoxia in tumors, shifting cells to mitochondrial respi...
Deficiency of myeloid discoidin domain receptor 2 aggravates melanoma lung and bone metastasis
Deficiency of myeloid discoidin domain receptor 2 aggravates melanoma lung and bone metastasis
Melanoma, one of the most prevalent cancers worldwide, frequently metastasizes to the lung and bones. Tumor-associated mac...
DYNC2H1 mutation as a potential predictive biomarker for immune checkpoint inhibitor efficacy in NSCLC and melanoma
DYNC2H1 mutation as a potential predictive biomarker for immune checkpoint inhibitor efficacy in NSCLC and melanoma
Dynein cytoplasmic 2 heavy chain 1 (DYNC2H1) is reported to play a potential role in cancer immunotherapy. However, the as...
Efficacy and safety of fruquintinib plus capecitabine as first-line treatment in patients with metastatic colorectal cancer ineligible for intravenous chemotherapy: a two-stage, single-armed, phase II study
Efficacy and safety of fruquintinib plus capecitabine as first-line treatment in patients with metastatic colorectal cancer ineligible for intravenous chemotherapy: a two-stage, single-armed, phase II study
Fruquintinib has been recommended for treating refractory metastatic colorectal cancer. This single-arm, phase II study ex...
HDAC6 inhibition through WT161 synergizes with temozolomide, induces apoptosis, reduces cell motility, and decreases β-catenin levels in glioblastoma cells
HDAC6 inhibition through WT161 synergizes with temozolomide, induces apoptosis, reduces cell motility, and decreases β-catenin levels in glioblastoma cells
Glioblastoma multiforme (GBM) accounts for 70% of all primary malignancies of the central nervous system. Current treatmen...
Cardioprotective effects of PARP inhibitors for platinum-agent induced cardiotoxicity
Cardioprotective effects of PARP inhibitors for platinum-agent induced cardiotoxicity
Poly(ADP-ribose) polymerase (PARP) inhibitors may have cardioprotective properties. This study aimed to evaluate the poten...
Progress of KRAS G12C inhibitors in the treatment of refractory colorectal cancer and strategies for drug resistance response
Progress of KRAS G12C inhibitors in the treatment of refractory colorectal cancer and strategies for drug resistance response
Colorectal cancer is the third most prevalent cancer in the world. Early screening and detection of tumours, active surgic...
Challenging and new opportunities for prodrug technology
Challenging and new opportunities for prodrug technology
Research on prodrug technology has opened new avenues for site-directed chemotherapy rather than systemic chemotherapy. Th...
A phase I dose-escalation and expansion study of RMX1002, a selective E-type prostanoid receptor 4 antagonist, as monotherapy and in combination with anti-PD-1 antibody in advanced solid tumors
A phase I dose-escalation and expansion study of RMX1002, a selective E-type prostanoid receptor 4 antagonist, as monotherapy and in combination with anti-PD-1 antibody in advanced solid tumors
RMX1002 (grapiprant) is a selective E-type prostanoid receptor 4 (EP4) antagonist and a promising candidate for cancer the...
A novel anti-HER2/EGFR bispecific antibody–drug conjugate demonstrates promising antitumor efficacy and overcomes resistance to HER2- or EGFR-targeted ADCs
A novel anti-HER2/EGFR bispecific antibody–drug conjugate demonstrates promising antitumor efficacy and overcomes resistance to HER2- or EGFR-targeted ADCs
HER2 and EGFR are frequently co-expressed in various tumors. While antibody–drug conjugates (ADCs) targeting HER2, s...
Retrospective analysis of clinical features of nivolumab-induced immune-related pancreatitis
Retrospective analysis of clinical features of nivolumab-induced immune-related pancreatitis
To study the clinical features of nivolumab-induced immune-related pancreatitis and to provide evidence for its recognitio...
From development to clinical success: the journey of established and next-generation BTK inhibitors
From development to clinical success: the journey of established and next-generation BTK inhibitors
Over the past decade, Bruton’s tyrosine kinase (BTK) has emerged as a pivotal therapeutic target for B-cell malignan...
A phase I safety and efficacy clinical trial of plocabulin and gemcitabine in patients with advanced solid tumors
A phase I safety and efficacy clinical trial of plocabulin and gemcitabine in patients with advanced solid tumors
Plocabulin (Plo) induces depolymerization of tubulin fibers with disorganization and fragmentation of the microtubule netw...
A randomized phase 1 study of safety, tolerability, and pharmacokinetics of MK-1088, a novel dual adenosine receptor antagonist, in healthy adult participants
A randomized phase 1 study of safety, tolerability, and pharmacokinetics of MK-1088, a novel dual adenosine receptor antagonist, in healthy adult participants
This phase 1 first-in-human study evaluated the safety, tolerability, and pharmacokinetics of MK-1088, a novel, small-mole...
Post-marketing safety concerns with relugolix: a disproportionality analysis of the FDA adverse event reporting system
Post-marketing safety concerns with relugolix: a disproportionality analysis of the FDA adverse event reporting system
Background: Relugolix has been used to treat advanced prostate cancer. This study assessed adverse events (AEs) associated...
Clinical characteristics, treatment, and outcomes of pembrolizumab-induced uveitis
Clinical characteristics, treatment, and outcomes of pembrolizumab-induced uveitis
Pembrolizumab has been associated with episodes of uveitis, and the clinical characteristics between them are unknown. The...
Design optimization of Fucoidan-coating Cationic Liposomes for enhance Gemcitabine delivery
Design optimization of Fucoidan-coating Cationic Liposomes for enhance Gemcitabine delivery
Obstacles facing chemotherapeutic drugs for cancers led scientists to load Gemcitabine (GEM) into nanocarriers like liposo...
Broad-spectrum anti-cancer activity of fused human arginase variants
Broad-spectrum anti-cancer activity of fused human arginase variants
The rapid increase in cancer cases worldwide necessitates the development of novel therapeutic approaches. Therapies targe...
Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort
Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort
The association between depth of response (DpR) and treatment outcomes has been documented across various types of cancer....
Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer
Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer
Sitravatinib (MGCD516) is an oral inhibitor of several closely related oncogenic tyrosine kinase receptors that include VE...
Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma
Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma
Although immune checkpoint inhibitors (ICI) are used for unresectable hepatocellular carcinoma (HCC), it is unclear whethe...
Phase II trial of multi-kinase inhibitor ESK981 in patients with metastatic castration-resistant prostate cancer
Phase II trial of multi-kinase inhibitor ESK981 in patients with metastatic castration-resistant prostate cancer
ESK981 is a potent tyrosine kinase and PIKfyve lipid kinase inhibitor. This phase II trial evaluated the efficacy of ESK98...
A phase 1b study of the ERK inhibitor MK-8353 plus pembrolizumab in patients with advanced solid tumors
A phase 1b study of the ERK inhibitor MK-8353 plus pembrolizumab in patients with advanced solid tumors
Combining a checkpoint inhibitor with an inhibitor of extracellular signal-regulated kinase (ERK) may result in synergisti...
Targeting MDM2-mediated suppression of p53 with idasanutlin: a promising therapeutic approach for acute lymphoblastic leukemia
Targeting MDM2-mediated suppression of p53 with idasanutlin: a promising therapeutic approach for acute lymphoblastic leukemia
Despite available treatments for acute lymphoblastic leukemia (ALL), the disease’s high clinical variability necessi...
Gremlin1: a BMP antagonist with therapeutic potential in Oncology
Gremlin1: a BMP antagonist with therapeutic potential in Oncology
Gremlins, originating from early 20th-century Western folklore, are mythical creatures known for causing mechanical malfun...
Effect of PAWI-2 on pancreatic cancer stem cell tumors
Effect of PAWI-2 on pancreatic cancer stem cell tumors
Worldwide, pancreatic cancer (PC) is a major health problem and almost 0.5 million people were diagnosed with PC ...
Load More
format_indent_increase